TAK Stock Analysis: Buy, Sell, or Hold?
TAK - Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$16.39
-0.10 (-0.61%)
▼
5d:
-3.36%
30d:
+3.28%
90d:
-8.02%
BUY
HIGH Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Jul 30, 2026
14d
Get Alerted When TAK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TAK appears deeply undervalued. Market expects -0.7% annual earnings decline despite 330% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: TAK appears deeply undervalued. Market expects -0.7% annual earnings decline despite 330% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$22.97
28.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TAK is currently trading at $16.39, which is considered slightly high relative to its 30-day fair value range of $15.58 to $16.50. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.2) compared to its historical average (0.2). Remarkably, the market is currently pricing in an annual earnings decline of 0.7% over the next few years. This pessimistic expectation contrasts with the company's recent 330.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, TAK is in a strong downtrend. Immediate support is located at $15.84, while resistance sits at $17.12.
Market Sentiment: TAK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.97 (+27.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TAK is in a strong downtrend. Immediate support is located at $15.84, while resistance sits at $17.12.
Market Sentiment: TAK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.97 (+27.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$15.58 -
$16.50
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
76.2%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 27.9% below Wall St target ($20.97)
Trading Range Analysis
30-Day Trading Range
$15.58 -
$16.50
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$15.84
Resistance Level
$17.12
Current Trend
Strong Downtrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.17
Wall Street Target
$20.97
(+27.9%)
Revenue Growth (YoY)
3.9%
Earnings Growth (YoY)
330.2%
Profit Margin
-3.4%
Valuation Discount vs History
-0.7% cheaper
PE vs Historical
0.2 vs 0.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.7%
(market-implied from PE analysis)
1-Year Target
$16.28
(-1%)
2-Year Target
$16.16
(-1%)
3-Year Target
$16.05
(-2%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
$18.60
(+14%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 93.0%)
$6981.89
(+42499%)
Base:
(SPY PE: 0.2, Growth: 93.0%)
$55.32
(+238%)
Bear:
(PE: 0.1, Growth: 93.0%)
$47.02
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 0.2 to 0.2
Stabilization Target:
$19.00
(+15.9%)
PE Expansion Potential:
+15.9%
Share & Embed Analysis
Last updated: July 14, 2026 7:21 PM ET
Data refreshes hourly during market hours. Next update: 8:21 PM
Data refreshes hourly during market hours. Next update: 8:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TAK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 54 HOLD |
